InvestorsHub Logo

Pennybuster

03/14/16 5:14 PM

#14387 RE: Pennybuster #14386

$OREX $MAXD Nice Days. $CPXX Going Nuts After Hours Here.



Form 8-K for CELATOR PHARMACEUTICALS INC

14-Mar-2016

Other Events, Financial Statements and Exhibits


Item 8.01. Other Events.
On March 14, 2016, we announced positive results from the Phase 3 trial of VYXEOS? (cytarabine: daunorubicin) Liposome for Injection (also known as CPX-351) in patients with high-risk (secondary) acute myeloid leukemia (AML) compared to the standard of care regimen of cytarabine and daunorubicin known as 7+3. The trial met its primary endpoint demonstrating a statistically significant improvement in overall survival.

The full text of our press release issued in connection with the announcement is attached to this Form 8-K current report as Exhibit 99.1. We incorporate the press release by reference into this Item 8.01 as if fully set forth herein.



Item 9.01. Financial Statements and Exhibits.
Exhibit No. Exhibit Description
99.1 Press release dated March 14, 2016